SecurityAC.WD / Associated Capital Group, Inc. (045528106)
President & CEOJAMIESON DOUGLAS R
IndustrySecurity Brokers, Dealers, and Flotation Companies
Institutional Owners62
Institutional Shares3,148,810 - 13.63%
Common Stock Shares Outstanding23,100,000 shares (as of 2018-03-31)
Institutional Value$ 153,554,000 USD
Related AC / Associated Capital Group, Inc.

Institutional Stock Ownership and Shareholders()

AC.WD / Associated Capital Group, Inc. Institutional Ownership

Associated Capital Group, Inc. (NYSE:AC.WD) has 62 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 3,148,810 shares. Largest shareholders include Horizon Kinetics LLC, Vanguard Group Inc, BlackRock Inc., Lombard Odier Asset Management (USA) Corp, Royce & Associates LLC, BlackRock Institutional Trust Company, N.A., BlackRock Fund Advisors, Mad River Investors, Rice Hall James & Associates, Llc, and S. Muoio & Co. Llc.
Associated Capital Group, Inc. (NYSE:AC.WD) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/ac.wd"><img src="https://images.fintel.io/us-ac.wd-so.png" alt="AC.WD / Associated Capital Group, Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-07 13F-HR SCHWAB CHARLES INVESTMENT MANAGEMENT INC 13,100 10,400 -20.61 447 390 -12.75
2018-05-17 13F-HR Legal & General Group Plc 1,215 753 -38.02 42 28 -33.33
2018-04-25 13F-HR RICE HALL JAMES & ASSOCIATES, LLC 75,368 73,451 -2.54 2,570 2,751 7.04
2018-05-15 13F-HR BARR E S & CO 7,200 6,500 -9.72 246 243 -1.22
2018-05-14 13F-HR MACKENZIE FINANCIAL CORP 15,900 595
2018-05-04 13F-HR Swiss National Bank 7,700 0 -100.00 263 0 -100.00
2018-05-15 13F-HR STATE STREET CORP 114,812 29,444 -74.35 3,910 1,102 -71.82
2018-05-15 13F-HR BARCLAYS PLC 1,013 849 -16.19 34 32 -5.88
2018-05-11 13F-HR Covington Capital Management 7 8 14.29
2018-05-10 13F-HR JP Morgan Chase & Co 14,327 17,551 22.50 489 657 34.36
2017-02-10 13F-HR BlackRock Advisors LLC 2,458 2,659 8.18 87 87 0.00
2018-04-17 13F-HR Guinness Asset Management Ltd 3,000 3,000 0.00 102 112 9.80
2018-05-15 13F-HR TWO SIGMA ADVISERS, LP 9,300 0 -100.00 317 0 -100.00
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 7,269 6,451 -11.25 248 241 -2.82
2018-05-14 13F-HR Renaissance Technologies LLC 71,000 34,200 -51.83 2,421 1,281 -47.09
2018-05-14 13F-HR BROWN BROTHERS HARRIMAN & CO 40 0 -100.00 1 0 -100.00
2017-08-18 13F-HR WFG Advisors, LP 980 1,470 50.00 35 50 42.86
2018-05-14 13F-HR S. MUOIO & CO. LLC 55,183 54,183 -1.81 1,882 2,029 7.81
2018-05-15 13F-HR LPL Financial LLC 15,023 14,423 -3.99 512 540 5.47
2018-07-13 13F-HR BANK OF MONTREAL /CAN/ 27 45 66.67 1 2 100.00
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 561 503 -10.34 19 19 0.00
2018-05-14 13F-HR RAYMOND JAMES & ASSOCIATES 22,565 22,825 1.15 769 855 11.18
2018-05-16 13F-HR ASSETMARK, INC 1,926 72
2018-05-15 13F-HR UBS Group AG 470 1,510 221.28 16 56 250.00
2018-05-15 13F-HR Ameritas Investment Partners, Inc. 520 520 0.00 18 19 5.56
2018-05-11 13F-HR CITIGROUP INC 680 733 7.79 23 28 21.74
2018-05-14 13F-HR PARAMETRIC PORTFOLIO ASSOCIATES LLC 7,148 10,516 47.12 244 394 61.48
2018-05-14 13F-HR Royce & Associates LLC 220,212 220,212 0.00 7,509 8,247 9.83
2018-05-11 13F-HR VAN ECK ASSOCIATES CORP 1,497 1,434 -4.21 51 54 5.88
2018-05-15 13F-HR Parallax Volatility Advisers, L.P. 756 0 -100.00 26 0 -100.00
2018-05-11 13F-HR Russell Investments Group, Ltd. 3,466 1,733 -50.00 119 65 -45.38
2018-07-18 13F-HR NISA INVESTMENT ADVISORS L.L.C. 3,300 3,300 0.00 114 125 9.65
2018-05-11 13F-HR DIMENSIONAL FUND ADVISORS LP 50,366 12,677 -74.83 1,717 475 -72.34
2018-05-14 13F-HR MORGAN STANLEY 9,067 8,602 -5.13 309 322 4.21
2018-05-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 1,765 1,765 0.00 60 66 10.00
2018-05-15 13F-HR Bank of New York Mellon Corp 40,080 38,205 -4.68 1,367 1,431 4.68
2018-04-20 13F-HR STRS OHIO 100 100 0.00 3 3 0.00
2018-05-11 13F-HR SEI INVESTMENTS CO 52,239 0 -100.00 5,470 0 -100.00
2018-05-11 13F-HR PNC FINANCIAL SERVICES GROUP, INC. 10,431 10,431 0.00 355 390 9.86
2017-02-10 13F-HR BlackRock Fund Advisors 118,478 144,230 21.74 4,201 4,738 12.78
2018-05-10 13F-HR NEW YORK STATE COMMON RETIREMENT FUND 5,800 5,800 0.00 198 217 9.60
2018-05-14 13F-HR Adviser Investments LLC 600 22
2018-05-15 13F-HR Lombard Odier Asset Management (USA) Corp Call 164,100 221,200 34.80 4,247 5,922 39.44
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 38,053 37,065 -2.60 1,297 1,388 7.02
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 157,024 157,553 0.34 5,568 5,176 -7.04
2018-05-14 13F-HR TIAA CREF INVESTMENT MANAGEMENT LLC 21,988 13,458 -38.79 750 504 -32.80
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 2,020 4,683 131.83 69 175 153.62
2018-05-10 13F-HR BEACH INVESTMENT COUNSEL INC/PA 11,888 0 -100.00 405 0 -100.00
2018-05-10 13F-HR GREAT WEST LIFE ASSURANCE CO /CAN/ 1,175 1,187 1.02 40 44 10.00
2018-04-23 13F-HR MAD RIVER INVESTORS 91,950 92,350 0.44 3,135 3,459 10.33
2018-05-15 13F-HR Horizon Kinetics LLC 1,326,041 1,312,017 -1.06 45,218 49,135 8.66
2018-05-15 13F-HR DEUTSCHE BANK AG\ 28,241 4,500 -84.07 961 166 -82.73
2018-05-15 13F-HR Ancora Advisors, LLC 0 10,000 0 374
2018-05-02 13F-HR RHUMBLINE ADVISERS 6,319 5,844 -7.52 215 219 1.86
2018-05-14 13F-HR ALLIANCEBERNSTEIN L.P. 15,853 15,653 -1.26 541 586 8.32
2018-05-15 13F-HR VANGUARD GROUP INC 375,271 300,837 -19.83 12,796 11,266 -11.96
2018-05-08 13F-HR US BANCORP \DE\ 7,000 7,000 0.00 239 262 9.62
2018-05-09 13F-HR NORTHERN TRUST CORP 76,586 46,685 -39.04 2,611 1,748 -33.05
2018-05-14 13F-HR TEACHERS ADVISORS INC 9,452 9,452 0.00 322 354 9.94
2018-05-09 13F-HR BlackRock Inc. 336,248 285,050 -15.23 11,466 10,676 -6.89
2018-05-15 13F-HR Tower Research Capital LLC (TRC) 102 0 -100.00 3 0 -100.00
2018-05-11 13F-HR BNP PARIBAS ARBITRAGE, SA 1,370 992 -27.59 46,717 37,150 -20.48
2017-02-10 13F-HR BlackRock Group LTD 1,295 1,295 0.00 46 42 -8.70
2017-02-10 13F-HR BlackRock Investment Management, LLC 21,158 21,312 0.73 750 700 -6.67
2018-05-07 13F-HR AMERICAN INTERNATIONAL GROUP INC 3,029 2,494 -17.66 103 93 -9.71
2018-07-13 13F-HR FINANCIAL & INVESTMENT MANAGEMENT GROUP LTD 156,270 49,606 -68.26 5,852 1,883 -67.82
2018-04-27 13F-HR Chicago Partners Investment Group LLC 510 510 0.00 17 19 11.76
2018-05-15 13F-HR CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 7,925 5,942 -25.02 270 223 -17.41
2018-05-15 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 4,707 4,424 -6.01 160 166 3.75

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Gamco: Poorly Performing Equity Manager Has Lost Its Mojo

2018-05-29 seekingalpha
Gamco Investors, founded by Mario Gabelli, was built to where it is today on his reputation for outperformance. (16-1)

CUSIP: 045528106